

## QIBA Dynamic Contrast-Enhanced (DCE) MRI Biomarker Committee (BC) Call

Monday, September 13, 2021, at 11 a.m. (CT)

### Call Summary

#### In attendance

*Caroline Chung, MD (Co-Chair)*

*Hendrik Laue, PhD (Co-Chair)*

Trevor Andrews, PhD

Cristina Lavini, PhD

#### RSNA staff

Joe Koudelik

Susan Stanfa

RSNA Staff attempt to capture all committee members participating on Zoom calls. However, **if attendees join only by phone, or do not use a recognizable name, identification is not possible.** Participants are welcome to contact RSNA staff at [QIBA@RSNA.org](mailto:QIBA@RSNA.org) if their attendance is not reflected on the call summaries.

#### Update on DCE-MRI Profile

- The [Public Comment Resolutions Sheet](#) was referenced; details on resolutions reached through committee discussion and consensus are included
- DCE-MRI BC members are welcome to work on edits to the [Profile](#) currently in progress

#### The following comments submitted during the public comment period were addressed:

**Note:** below comments correspond to the [Stage 1: Public Comment version of the DCE-MRI Profile](#) posted on the [Profiles page](#) of the QIBA Wiki

- Trevor Andrews, PhD, was present to continue discussing comments from AAPM representatives
- More guidance needed re: the importance/rationale of using the same scanner and analysis software for longitudinal studies, as site pushback is expected; details are needed describing the expected variability when different equipment is used
  - Manufacturer should be consulted if changes affecting DCE-MRI are expected
  - If assessment procedures are successfully executed, there should not be a problem
  - Image post-processing should be documented by the manufacturer
  - Conducting multi-center study to be considered
  - The scanner manufacturer should be consulted re: whether new image improvement features need to be disabled
  - Scheduling a meeting with vendor representatives to discuss this issue was suggested
- Reference to be added to Assessment Procedure R1/T1 mapping to define action limits, e.g., a “marked deviation” for assessing drift needs to be identified
- Paragraph referencing DCE trial should be removed as it may be a remnant of the 2012 DCE-MRI Profile version 1.0
- Dr. Lavini to be consulted re: whether impact of echo time (TE) selection on signal (T2\*) discussion is needed in Section 3.6

**Next call:** Monday, September 27, 2021, at 11 a.m. (CT) [2<sup>nd</sup> & 4<sup>th</sup> Mondays of each month]